Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency

Still listed by CMS but carries a termination date, so it is not valid for a current date of service.

Terminated with effect from 2023-12-13. First published 2023. CMS still lists this code in the current quarterly file - it carries a termination date rather than being removed.